Clinical Trials
24 trialsNCT05414500 2026-04-09
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
Phase 1 Recruiting
NCT02616965 2025-04-04
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
Fox Chase Cancer Center
Phase 1 Completed
NCT04254107 2025-02-10
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase 1 Terminated
NCT03013933 2024-02-22
Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Completed
NCT03302728 2022-05-19
EpiBrentlen
Peter MacCallum Cancer Centre, Australia
Phase 1 Completed
NCT02086604 2022-02-17
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Washington University School of Medicine
Phase 1 Completed
NCT01830777 2020-04-14
Brentuximab Vedotin + Re-induction Chemotherapy for AML
Massachusetts General Hospital
Phase 1 Completed
NCT02254239 2019-12-12
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Mayo Clinic
Phase 1 Terminated
NCT02164006 2019-10-02
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
TG Therapeutics, Inc.
Phase 1 Completed
NCT02822586 2019-08-30
TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
Virginia Commonwealth University
Phase 1 Completed
NCT03373305 2019-04-30
Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
City of Hope Medical Center
Phase 1 Withdrawn
NCT01700751 2019-04-16
Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Washington University School of Medicine
Phase 1 Completed
NCT01900496 2018-10-17
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02780011 2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1 Withdrawn
NCT02280993 2018-03-13
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Unknown
NCT03205891 2018-01-17
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT01309789 2017-06-28
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
Seagen Inc.
Phase 1 Completed
NCT01950364 2016-05-11
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT01902160 2015-11-09
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00430846 2014-12-18
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Seagen Inc.
Phase 1 Completed
NCT00649584 2014-12-18
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Seagen Inc.
Phase 1 Terminated
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed
NCT01060904 2014-12-18
A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma
Seagen Inc.
Phase 1 Completed
NCT01026233 2014-12-12
Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed